Grifols (Grifols) Debt-to-Revenue : 1.43 (As of Dec. 2023)

View and export this data going back to 2011. Start your Free Trial

What is Grifols Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Grifols's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $979 Mil. Grifols's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $10,054 Mil. Grifols's annualized Revenue for the quarter that ended in Dec. 2023 was $7,719 Mil. Grifols's annualized Debt-to-Revenue for the quarter that ended in Dec. 2023 was 1.43.

Grifols Debt-to-Revenue Historical Data

The historical data trend for Grifols's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Grifols Debt-to-Revenue Chart

Grifols Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Revenue

Get a 7-Day Free Trial

1.39

1.29

1.89

1.61

1.54

Grifols Quarterly Data
	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Dec21	Jun22	Sep22	Dec22	Jun23	Sep23	Dec23
Debt-to-Revenue	Get a 7-Day Free Trial															-	1.42	1.64	1.73	1.43

Competitive Comparison of Grifols's Debt-to-Revenue

For the Drug Manufacturers - General subindustry, Grifols's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Grifols's Debt-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Grifols's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Grifols's Debt-to-Revenue falls into.

Grifols Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Grifols's Debt-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(979.188	+	10054.007)	/	7188.634
	=	1.53

Grifols's annualized Debt-to-Revenue for the quarter that ended in Dec. 2023 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(979.188	+	10054.007)	/	7718.86
	=	1.43

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Dec. 2023) Revenue data.

Grifols Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Grifols's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Grifols (Grifols) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Grifols SA (NAS:GRFS) » Definitions » Debt-to-Revenue

Comparable Companies

Traded in Other Exchanges

GIKLY:USA GIFOF:USA GIFLF:USA GRFP:Mexico GRFe:UK GRFPe:UK 0RDV:UK 0RDU:UK GRF.P:Spain GRF:Spain G0F0:Germany G0F:Germany G0FB:Germany OZTA:Germany OZTA:Germany G0FB:Germany

Address

Avinguda de la Generalitat, 152-158, Parc de Negocis Can Sant Joan, Sant Cugat del Valles, Barcelona, ESP, 08174

Website

https://www.grifols.com

As a vertically integrated plasma derivative producer, Spain-based Grifols collects plasma and then manufactures and sells plasma-derived products globally. By acquiring Talecris in 2011, Grifols dramatically expanded its plasma-derived product portfolio, and the firm's biopharma business contributed 83% of sales in 2022. Grifols also has smaller segments including diagnostics and biosupplies. Diagnostics is roughly 10% of revenue following the Biotest acquisition.